A Phase Ib/II, Open-label, Multi-center Study of SHR2554 With CHOP/CHOEP in Treatment-naïve Patients With Peripheral T-cell Lymphoma
Latest Information Update: 17 May 2024
At a glance
- Drugs SHR-2554 (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 11 May 2024 Status changed from not yet recruiting to recruiting.
- 20 Dec 2023 New trial record